About Contact Us Careers

Osteoarthritis Therapeutics Market Size & Share, by Drug Type (Disease-Modifying Osteoarthritis Drugs (DMOADs), Symptomatic Pain Relief Drugs, Combination Therapies); Therapy Type; Route of Administration; End User; Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

  • Report ID: 195
  • Published Date: Sep 12, 2025
  • Report Format: PDF, PPT

Osteoarthritis Therapeutics Market Outlook:

Osteoarthritis Therapeutics Market size was valued at USD 10.83 billion in 2025 and is projected to reach USD 26.60 billion by the end of 2035, rising at a CAGR of 9.4% during the forecast period, i.e., 2026-2035. In 2026, the industry size of osteoarthritis therapeutics is assessed at USD 11.85 billion.

The global market is experiencing change in a variety of ways, and, in particular, the sector is focused on revolutionary advances in therapies and technologies. Of particular note are disease-modifying osteoarthritis drugs (DMOADs), which aim to alter the progression of the disease rather than just treating its symptoms. DMOADs represent treatments that can repair cartilage and prevent joint damage, which certainly fills a critical but unmet medical need. At the same time, the advent of digital health technologies is delivered by allowing for continuous monitoring and tracking, personalized treatment plans, and improving patient adherence and engagement. In addition, strategies in personalized medicine are being fast-tracked as a result of advancements in stem cell research focusing on cartilage regeneration.

Regenerative treatments (i.e., injectable platelet-rich plasma (PRP) or stem cells) are finding wider acceptance as they are believed to restore joint function while alleviating pain and restoring joint flexibility with a lower risk of clinically significant adverse effects compared to traditional treatments. Similarly, requests for minimally invasive procedures like genicular artery embolization (GAE) are being directed more frequently toward hospitals and interventional radiologists as patients want to learn more about options that could provide effective pain relief without necessitating surgery. Overall, as pharmaceutical companies and emerging biotechnology companies continue to drive rapid innovation, partnerships will increasingly straddle a divide that combines lessons learned from years of applied biomedical research in mitigating osteoarthritis pain.

Osteoarthritis Therapeutics Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Rising geriatric population: According to the World Health Organization, by 2030, there will be 1.4 billion persons over 60 in the world, up from 1.1 billion in 2023. In emerging nations, this trend is more noticeable and swifter. The increasing aging population worldwide is a primary driver for the osteoarthritis therapeutics sector. Osteoarthritis primarily affects older adults due to the natural wear and tear of joints over time. As life expectancy rises, a larger proportion of the population is vulnerable to joint degeneration and related disorders. This demographic shift significantly raises the demand for effective therapeutics to manage symptoms and improve quality of life. Governments and healthcare systems are also focusing more on age-related diseases, driving investments in osteoarthritis treatments.
  • Rising prevalence of osteoarthritis and related risk factors: The Centers for Disease Control and Prevention estimates that women were more likely than males to have arthritis (21.5%) in 2022, with the age-adjusted prevalence of diagnosed arthritis among individuals aged 18 and older being 18.9%. The increasing prevalence of osteoarthritis is propelled by various factors, including obesity, sedentary lifestyle habits, and joint injuries. Increased weight on joints, especially on weight-bearing joints such as knees and hips, leads to further cartilage deterioration. Increased activity in sports leads to an increased prevalence of injuries, both in sports and in the workplace, leading to an earlier incidence of osteoarthritis.
  • Advancements in disease-modifying osteoarthritis drugs (DMOADs): The discovery of new disease-modifying osteoarthritis drugs represents a major growth driver. DMOADs are differentiated from traditional therapeutics that manage osteoarthritis pain and inflammation in ways that create and promote long-term benefits by repairing cartilage and stopping or slowing the progression of the disease states. Healthcare providers and their patients are anticipating more of these treatments as available therapies emerge from the clinical trial phase and research results indicate the potential to impact their disease outcomes.

Challenges

  • Limited disease-modifying treatment options: Despite continuing research, genuine disease-modifying osteoarthritis drugs (DMOAD) are in short supply. Most treatments available are designed to relieve symptoms, not change the course of joint degeneration. As a result, long-term treatment efficacy for both patients and physicians is limited; disease management often tops patient outcomes related to achieving a cure.
  • High cost of advanced therapies: Emerging modalities of treatment, such as biologics, regenerative medicine, and minimally invasive techniques, can be expensive, thus obstructing access and often complicating access for patients in low and middle-income populations. Barriers to affordability still exist, both for the patients and the healthcare system, and can pose difficulties for the dissemination of cutting-edge therapies.

Country-Specific Prevalence Rates of Knee Osteoarthritis (KOA) in 2019

Country

KOA Prevalence Rate (per 100,000, 2019)

Notes

Japan

12,610.12

Highest prevalence rate, about 10x Somalia

Somalia

1,178.23

The lowest prevalence rate is mentioned

United Arab Emirates

Not reported

Exception: KOA prevalence/incidence/DALYs lower or not reported

Sources: Frontiers

Country and Regional Osteoarthritis (OA) Prevalence and Burden Estimates (2020)

Country/Region

OA Prevalent Cases / Rate

Notes

Southeast Asia

5,677.4 per 100,000 (UI 5029.8–6318.1)

Age-standardized prevalence rate in 2020

High-income Asia Pacific

8,632.7 per 100,000 (UI 7852.0–9469.1)

Highest age-standardized prevalence rate by region

Global (all countries)

595 million cases (7.6% of global population)

Total OA cases in 2020

Global (adults 70+)

7th ranked cause of Years Lived with Disability (YLDs)

Indicates a significant OA burden in elderly

Source: NIH

Osteoarthritis Therapeutics Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

9.4%

Base Year Market Size (2025)

USD 10.83 billion

Forecast Year Market Size (2035)

USD 26.60 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Osteoarthritis Therapeutics Market Segmentation:

Drug Type Segment Analysis 

The disease-modifying osteoarthritis drugs (DMOADs) segment is estimated to account for the largest share of 40% in the market over the discussed timeframe. DMOADs are positioned in the first-line group of osteoarthritis treatment options because they are indicated to modify disease progression instead of just controlling symptoms. Per the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), DMOADs may improve cartilage health and slow or stop the deterioration of the joint, ultimately, filling a critical unmet need. There is a rise in R&D spending - combined with a regulatory urgency to get innovative therapies to market - is contributing to greater development for DMOADs. Furthermore, more patients understand early intervention and are incurring more symptomatic management, are further increases the growth potential in the segment.

Therapy Type Segment Analysis  

The regenerative therapies (stem cell & PRP) segment is poised to dominate the osteoarthritis therapeutics market with a share of 30% during the analyzed period. PRP (platelet-rich plasma) injections and stem cell therapy have the potential to relieve pain and regenerate cartilage. The Arthritis Foundation states that stem cells, along with PRP, can help improve joint function, with fewer side effects than other therapies. As government-funded agreements and clinical trials continue to expand the evidence base for stem cells and PRP therapies, these therapies will continue to be more commonly used in clinical practice.

Route of Administration Segment Analysis

During the examined period, the intra-articular injections segment is expected to hold a 24% market share in the osteoarthritis therapeutics industry. Injections administered directly into the joint (e.g. steroids or hyaluronic acid) will remain a treatment option to try because these injections have a therapeutic effect on the joints being injected. In fact, the Centers for Disease Control and Prevention (CDC) speaks specifically to the use of intra-articular injections in the management of pain and improvement of mobility for patients with osteoarthritis. As long as injections are accepted, easy to give, and paid for by insurance, this sub-segment of injections will continue to be a steady source of revenue.

Our in-depth analysis of the osteoarthritis therapeutics market includes the following segments: 

Segments

Subsegments

Drug Type
  • Disease-Modifying Osteoarthritis Drugs (DMOADs)
  • Symptomatic Pain Relief Drugs
  • Combination Therapies

Therapy Type
  • Regenerative Therapies
    • Stem Cell Therapy
    • PRP
  • Conventional Pharmacological Therapies
  • Surgical Interventions
    • Minimally Invasive Procedures

Route of Administration
  • Oral
  • Intra-Articular Injection
  • Topical

End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Home Care Settings

Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Osteoarthritis Therapeutics Market - Regional Analysis

North America Market Insights 

North America is anticipated to capture the highest share of 38% in the global osteoarthritis therapeutics market by the end of 2035. The region has a sizable and aging population, which in turn increases the prevalence of osteoarthritis (OA), a degenerative condition that mainly impacts older adults. Moreover, North America has a well-established healthcare ecosystem with good access to diagnostic technology and specialty orthopedic treatment that allows for early diagnosis and treatment.

The U.S. ranks first due to its sizable older demographic with an increased prevalence of osteoarthritis. It also has developed healthcare systems, broad insurance coverage, and significant investment in biomedical research that incentivizes a very fast transition from discovery to adoption of new and innovative therapeutics, including disease-modifying osteoarthritis drugs (DMOADs) and regenerative therapies. In addition, it has a friendlier regulatory process and more proactive healthcare systems, which also encourage growth in the market. 

Canada's market growth is driven by an increase in the occurrence of osteoarthritis with its aging population and the general publicly funded healthcare systems, which create access to better diagnostics and treatment. Additionally, government initiatives that promote musculoskeletal health and funding for regenerative medicine research all dipped into Canada's increasing market share.

Europe Market Insights 

Throughout the projection period, Europe is anticipated to experience a strong CAGR in the global osteoarthritis therapeutics market due to the established healthcare systems, increasing healthcare spending, and increasing prevalence of osteoarthritis due to aging populations. Countries like Germany, the UK, and France currently have advanced diagnostic and therapeutic facilities that allow for early intervention and continued treatment of osteoarthritis. In addition, the support of government and healthcare policies along with reimbursement enable the use of advanced therapies like disease-modifying drugs appropriate and regenerative therapies more acceptable. Europe has strong pharmaceutical and medical devices industry with substantial scientific research and development into osteoarthritis and public health awareness and promotion.

A well-established healthcare system, and a growing elderly population create strong demand for osteoarthritis therapeutics in France. The country also has a firm reimbursement structure that allows patients to have access to new medications. Moreover, an environment full of active research and development to manage osteoarthritis reinforces its prominence as a market.

Germany has a strong market share with its sophisticated medical infrastructure systems and large healthcare expenditures. Germany's focus on early diagnosis, disease management, and adoption of new therapies, strong clinical research, and government programs, drives demand for osteoarthritis therapeutics.

APAC Market Insights

Asia Pacific is expected to have a substantial CAGR in the global osteoarthritis therapeutics market during the forecast period. The growth in this area is largely fueled by lifestyle changes, including more urban living, sedentary habits, and rising obesity rates. Countries like China, India, and Japan are seeing a notable increase in joint-related issues as life expectancy rises and healthcare becomes more accessible. On top of that, the development of healthcare infrastructure, government efforts to enhance musculoskeletal health, and higher disposable incomes are all driving the uptake of advanced osteoarthritis treatments in the region.

India's increasing elderly population, along with a heightened awareness of osteoarthritis, is fueling demand in this rapidly evolving healthcare market. With more investments in healthcare infrastructure, better access to diagnostics, and government efforts aimed at enhancing chronic disease management, the market is set to grow. On top of that, the affordability of treatments and the rise in medical tourism are boosting India's share in the healthcare sector.

China's market is really taking off. The growth is driven by its huge population, an aging demographic, and an increasing number of osteoarthritis cases that are often linked to lifestyle changes and urban living. The government's strong focus on healthcare reforms, combined with rising healthcare expenditures and improved pharmaceutical research and development, is setting the stage for the adoption of innovative osteoarthritis treatments. This positions China as a significant player in this expanding sector.

Osteoarthritis Therapeutics Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Osteoarthritis Therapeutics Market Players:

    The osteoarthritis therapeutics industry is quite lively, with both major pharmaceutical companies and up-and-coming biotech firms competing fiercely for their slice of the pie. Big names like Sanofi, GlaxoSmithKline, and Pfizer are using their robust research and development capabilities, along with their vast distribution networks, to stay ahead of the game. For instance, the products of Sanofi Synvisc and Synvisc One are available in more than 60 countries, thanks to hefty investments in R&D.

    Company Name

    Country of Origin

    Market Share (%)

    Sanofi S.A.

    France

    15.2%

    GlaxoSmithKline plc

    United Kingdom

    12.5%

    Pfizer Inc.

    United States

    10.8%

    Bayer AG

    Germany

    9.7%

    Zimmer Biomet Holdings, Inc.

    United States

    8.9%

    Novartis AG

    Switzerland

    xx%

    Anika Therapeutics, Inc.

    United States

    xx%

    Assertio Therapeutics, Inc.

    United States

    xx%

    Bioventus LLC

    United States

    xx%

    Ferring Pharmaceuticals

    Switzerland

    xx%

    Flexion Therapeutics, Inc.

    United States

    xx%

    Arthrex, Inc.

    United States

    xx%

    Royal Biologics

    United States

    xx%

    Teva Pharmaceutical Industries Ltd.

    Israel

    xx%

    Abbott Laboratories

    United States

    xx%

    Eli Lilly and Company

    United States

    xx%

    Johnson & Johnson

    United States

    xx%

    Horizon Therapeutics PLC

    Ireland

    xx%

    Hanmi Pharm. Co., Ltd.

    South Korea

    xx%

    Kolon Life Science Inc.

    South Korea

    xx%

    Below are the areas covered for each company in the osteoarthritis therapeutics market: 

    • Company Overview 
    • Business Strategy 
    • Key Product Offerings 
    • Financial Performance 
    • Key Performance Indicators 
    • Risk Analysis 
    • Recent Development 
    • Regional Presence 
    • SWOT Analysis 

Recent Developments

  • In August 2025, Genascence Corporation declared that GNSC-001, a possible first-in-class gene therapy that blocks interleukin 1 (IL-1), has been given the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) to treat osteoarthritis (OA) in the knee. An optimized human interleukin-1 receptor antagonist (IL-1Ra), a naturally occurring protein that inhibits IL-1 signaling, is expressed via the genetic medicine GNSC-001, a recombinant adeno-associated viral vector.
  • In September 2024, Sun Pharma and Moebius Medical were granted fast-track designation by the USFDA for their non-opioid treatment MM-II, which is intended to alleviate knee pain caused by osteoarthritis. This designation permits a quicker review process and possibly a quicker approval process. The businesses want to apply for a CE Mark in the EU and start Phase 3 clinical studies.
  • Report ID: 195
  • Published Date: Sep 12, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of osteoarthritis therapeutics is evaluated at USD 10.83 billion.

Osteoarthritis Therapeutics Market size was valued at USD 10.83 billion in 2025 and is set to exceed USD 26.60 billion by 2035, registering over 9.4% CAGR during the forecast period i.e., between 2026-2035.

North America industry is expected to dominate majority revenue share of 38% by 2035, on the back of presence of ultra-modern healthcare infrastructure in the region.

The major players in the market are Sanofi S.A., GlaxoSmithKline plc, Pfizer Inc., Bayer AG, Zimmer Biomet Holdings, Inc., Novartis AG, Anika Therapeutics, Inc., Assertio Therapeutics, Inc., Bioventus LLC, Ferring Pharmaceuticals, Flexion Therapeutics, Inc., Arthrex, Inc., Royal Biologics, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Eli Lilly and Company, Johnson & Johnson.

Osteoarthritis Therapeutics Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos